Product Information
BRINZOLAMIDE 1% EYE DROPS is a generic product labeled by Padagis US LLC, priced at $9.4740 per ML under NDC 00574401215. Its NADAC has been published 147 times since Dec 13, 2023.
FDA first approved this application on Jul 28, 2023.
Strength
10 mg/mL
Manufacturer
Padagis US LLCNDC
00574401215
Classification
Generic
Dosage Form
SUSPENSION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
BRINZOLAMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA211914FDA Approved
7/28/2023
On Market Since
10/10/2023
Pharmacological Classes
Price Statistics
The NADAC for BRINZOLAMIDE 1% EYE DROPS has been published 147 times since Dec 13, 2023, and over the history we have for it it has declined 42.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.4740 per ML |
|---|---|
| All-time high | $17.2178 (Mar 12, 2025) |
| All-time low | $7.2636 (May 22, 2024) |
| 52-week high | $14.3013 |
| 52-week low | $9.4740 |
| Median price | $12.3315 |
| Average price | $12.1966 |
| Largest weekly change | -39.2% (May 22, 2024) |
| Weeks tracked | 147 |
| Tracking since | Dec 13, 2023 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 10% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
brinzolamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Carbonic Anhydrase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BRINZOLAMIDE 1% EYE DROPS?
The current National Average Drug Acquisition Cost (NADAC) for BRINZOLAMIDE 1% EYE DROPS, manufactured by Padagis US LLC, is $9.4740 per ML (NDC 00574401215), effective Sep 30, 2026.
How has the price of BRINZOLAMIDE 1% EYE DROPS changed over time?
Over the history we have for it, the NADAC for BRINZOLAMIDE 1% EYE DROPS has declined 42.5%. It has been tracked across 147 weekly CMS publications since Dec 13, 2023.
What are the highest and lowest recorded NADAC prices for BRINZOLAMIDE 1% EYE DROPS?
Since Dec 13, 2023, the NADAC for BRINZOLAMIDE 1% EYE DROPS has ranged from a low of $7.2636 (May 22, 2024) to a high of $17.2178 (Mar 12, 2025), with a median of $12.3315 per ML.
Are there cheaper alternatives to BRINZOLAMIDE 1% EYE DROPS?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BRINZOLAMIDE 1% EYE DROPS, is $8.5264 per ML — about 10% below BRINZOLAMIDE 1% EYE DROPS.
Who manufactures BRINZOLAMIDE 1% EYE DROPS?
BRINZOLAMIDE 1% EYE DROPS (NDC 00574401215) is labeled by Padagis US LLC, and CMS classifies it as a generic product.